UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2026
Commission File Number: 001-42810
YD Bio
Limited
12F., No. 3, Xingnan St.,
Nangang Dist.,
Taipei City 115001, Taiwan
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Issuance of Press Release
On August 11, 2026, YD Bio
Limited (the “Company”) issued a press release announcing the launch of two nutraceutical products in Taiwan, and its intent
to explore additional opportunities for collaboration through a repeatable physician-partnership model. A copy of the press release is
furnished as Exhibit 99.1 to this Report on Form 6-K (this “Report”) and is incorporated herein by reference.
The information contained
in this Report, except for any quotes provided in the press release, is hereby incorporated by reference into the Company’s Registration
Statement on Form S-8 (File No. 333-292554) to be a part thereof, to the extent not superseded by documents or reports subsequently filed
or furnished. This Report, including Exhibit 99.1, shall not otherwise be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such filing.
Forward Looking Statements
Matters discussed in this
report may constitute forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies,
future events or performance, and underlying assumptions and other statements, which are statements other than statements of historical
facts. The words “believe”, “may”, “intend”, “expect”, “pending”, “will”
and similar expressions identify forward-looking statements. The forward-looking statements in this report are based upon various assumptions.
Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant
uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we
will achieve or accomplish these expectations. Except as required by law, the Company disclaims any duty to update these forward-looking
statements.
EXHIBIT INDEX
The following exhibits are being filed herewith:
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release, dated August 11, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
August 11, 2026
| YD BIO LIMITED |
|
| |
|
| By: |
/s/ Edmund Hen |
|
| Name: |
Edmund Hen |
|
| Title: |
Chief Financial Officer |
|
Exhibit 99.1
YD Bio Launches a Physician-Partnership Initiative
in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association
and the Future Health Institute
Two chrono-nutrition formulations — a daytime
lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula — were developed in collaboration
with the Taiwan CDHA and FHI. The Company intends to expand this approach by exploring additional opportunities for collaboration with
other physicians and healthcare organizations.
TAIPEI, Taiwan, August 11, 2026 (GLOBE NEWSWIRE) — YD Bio Limited
(“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer
detection technology and ophthalmologic innovations, today announced its initial step towards building a physician-partnership ecosystem
and related consumer health commercialization capabilities in Taiwan with the launch of two chrono-nutrition formulations, a daytime lipid-soluble
“Golden Triangle” formula and a nighttime zinc-plus-calcium formula, developed in collaboration with the Taiwan Chronic Disease
Healthcare Association (“CDHA”) and the Future Health Institute, a widely followed physician-led health education platform
in Taiwan with more than 233,000 subscribers on YouTube (“FHI”).
This physician-partnership model represents a bottoms-up approach
in which practicing clinicians define the formulation requirements based on observations in their own patient populations, with YD Bio
contributing its expertise in product development, sourcing, quality oversight and commercialization.
The Company regards this collaboration with the Taiwan CDHA and FHI
as the initial deployment of a repeatable physician-partnership model rather than a standalone product launch and intends to explore additional
collaborations with other physicians and healthcare organizations.
Launch Highlights
| ● | Two
products launched in Taiwan under the YD Bio brand, built around a day-and-night chrono-nutrition
concept. |
| ● | Builds
a relationship with health-conscious consumers in Taiwan through its nutritional products
business, creating a foundation for future engagement with the Company’s regulated
diagnostics and clinical services offerings. |
| ● | Co-developed
with practicing physicians; each product carries the certification mark of the Taiwan CDHA
and a recommendation by the FHI. |
| ● | Physician-partnership
model designed to be repeatable — the Company intends to co-develop further formulations
with additional clinician partners for their respective patient communities. |
Why a Physician-Partnership Model
Consumer health companies often compete through marketing spend and
distribution channels. In contrast, YD Bio’s approach starts with physician insights and healthcare relationships: a physician with
an established practice and an engaged audience identifies a specific nutritional need in that population, then the formulation is built
to address such need. The Company believes this approach offers three advantages: (1) healthcare solutions grounded in observed patient
needs, (2) distribution through established relationships based on trust rather than purchased attention, and (3) a template that can
be applied again with each new physician partner.
For YD Bio, the model is intended to be capital-light
relative to the Company’s therapeutic and diagnostic programs, to generate recurring consumer revenue from repeat purchases, and
to build a relationship with health-conscious consumers in Taiwan that may support future engagement with the Company’s regulated
diagnostics and clinical services offerings.
Scientific Background
The daytime formulation reflects an area of research interest for
the Company’s scientific team. A review manuscript titled “Beyond Bone Health: Exploring the ‘Heart-Brain-Bone’
Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2),” co-authored by YD Bio personnel together with
physician-researchers in Taiwan, has been submitted to a peer-reviewed journal and is currently under review. The manuscript examines
the published literature on how long-chain omega-3 fatty acids, vitamin D3 and vitamin K2 (MK-7) act on shared biological pathways relating
to calcium handling, inflammation resolution and vascular function.
“Our vision is to build an integrated healthcare
platform that connects scientific innovation, clinical expertise and patient needs,” said Dr. Ethan Shen, Founder, Chairman
and Chief Executive Officer of YD Bio. “Our collaboration with physician-led organizations in Taiwan represents an important
step in expanding our healthcare ecosystem and building trusted relationships with healthcare professionals and consumers. While consumer
health products represent one component of our broader strategy, our focus remains on developing scalable healthcare solutions across
diagnostics, clinical services and life science commercialization.”
About YD Bio Limited
YD Bio is a U.S.-anchored public biotechnology company building an
integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization.
The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy
and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services.
In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in
Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s intention to co-develop additional products with further physician partners, the anticipated
capital requirements associated with, and the benefits and repeatability of, the physician-partnership model, the expected contribution
of consumer health activities to the Company’s business, and the submission and potential publication of the review manuscript submitted
to a peer-reviewed journal. Forward-looking statements are not guarantees of future performance and can be identified by words such as
“aim,” “intend,” “seek,” “believe,” “designed to,” “expects,”
“anticipates,” “plans,” “may,” “could,” “will” and other similar expressions.
The manuscript described above is a narrative review, has not been peer-reviewed or accepted for publication, and does not establish the
clinical safety or efficacy of any product. Actual results may differ materially from those expressed or implied by forward-looking statements
due to a variety of factors, including consumer demand and market acceptance; the Company’s ability to enter into and maintain partnerships
with physicians and other healthcare organizations; supply chain disruptions, manufacturing and quality considerations; competition; regulatory
and labeling requirements in Taiwan and other jurisdictions; the results of review of Company submissions by peer-reviewed journals; and
other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission (the “SEC”).
The Company cautions investors not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to update any forward-looking statements, except as required by law, and encourages investors to
review the risk factors in its Annual Report on Form 20-F and other SEC filings.
For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com
WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214
